Clonal evolution of chemotherapy-resistant urothelial carcinoma

Chemotherapy-resistant urothelial carcinoma has no uniformly curative therapy. Understanding how selective pressure from chemotherapy directs the evolution of urothelial carcinoma and shapes its clonal architecture is a central biological question with clinical implications. To address this question, we performed whole-exome sequencing and clonality analysis of 72 urothelial carcinoma samples, including 16 matched sets of primary and advanced tumors prospectively collected before and after chemotherapy. Our analysis provided several insights: (i) chemotherapy-treated urothelial carcinoma is characterized by intra-patient mutational heterogeneity, and the majority of mutations are not shared; (ii) both branching evolution and metastatic spread are very early events in the natural history of urothelial carcinoma; (iii) chemotherapy-treated urothelial carcinoma is enriched with clonal mutations involving L1 cell adhesion molecule (L1CAM) and integrin signaling pathways; and (iv) APOBEC-induced mutagenesis is clonally enriched in chemotherapy-treated urothelial carcinoma and continues to shape the evolution of urothelial carcinoma throughout its lifetime.

[1]  Roland L Dunbrack,et al.  Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. , 2015, European urology.

[2]  Matteo Benelli,et al.  Divergent clonal evolution of castration resistant neuroendocrine prostate cancer , 2016, Nature Medicine.

[3]  Jianjun Wang,et al.  Identification of Pold2 as a novel interaction partner of protein inhibitor of activated STAT2. , 2012, International journal of molecular medicine.

[4]  S. S. Koh,et al.  L1 cell adhesion molecule and epidermal growth factor receptor activation confer cisplatin resistance in intrahepatic cholangiocarcinoma cells. , 2012, Cancer letters.

[5]  P. Altevogt,et al.  L1-CAM in a membrane-bound or soluble form augments protection from apoptosis in ovarian carcinoma cells. , 2007, Gynecologic oncology.

[6]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[7]  Peter J. Campbell,et al.  C. elegans whole-genome sequencing reveals mutational signatures related to carcinogens and DNA repair deficiency , 2014, Genome research.

[8]  Christopher Haslett,et al.  Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo , 1999, Nature Medicine.

[9]  Vladimir Vacic,et al.  Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. , 2015, JAMA oncology.

[10]  M. Zöller.  Tetraspanins: push and pull in suppressing and promoting metastasis , 2009, Nature Reviews Cancer.

[11]  S. Gabriel,et al.  Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. , 2014, Cancer discovery.

[12]  Andrea Sottoriva,et al.  Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine , 2016, Trends in cancer.

[13]  H. Kijima,et al.  L1 Cell adhesion molecule (L1CAM) expression at the cancer invasive front is a novel prognostic marker of pancreatic ductal adenocarcinoma , 2011, Journal of surgical oncology.

[14]  H. Ozen.  Bladder cancer. , 1998, Current opinion in oncology.

[15]  P. Chanvorachote,et al.  Cisplatin at sub-toxic levels mediates integrin switch in lung cancer cells. , 2014, Anticancer research.

[16]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[17]  W. Fiedler,et al.  Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer , 2010, Expert opinion on investigational drugs.

[18]  K. Nixon,et al.  The Parsimony Ratchet, a New Method for Rapid Parsimony Analysis , 1999, Cladistics : the international journal of the Willi Hennig Society.

[19]  Gad Getz,et al.  An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers , 2015, Nature Genetics.

[20]  Gábor E. Tusnády,et al.  A comprehensive survey of the mutagenic impact of common cancer cytotoxics , 2016, Genome Biology.

[21]  Eung Suk Lee,et al.  Generation, characterization and preclinical studies of a human anti-L1CAM monoclonal antibody that cross-reacts with rodent L1CAM , 2016, mAbs.

[22]  Reuben S. Harris,et al.  Retroviral restriction by APOBEC proteins , 2004, Nature Reviews Immunology.

[23]  T. Mikkelsen,et al.  Direct contact with perivascular tumor cells enhances integrin αvβ3 signaling and migration of endothelial cells , 2016, Oncotarget.

[24]  A. Børresen-Dale,et al.  Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.

[25]  Trevor J Pugh,et al.  Oncotator: Cancer Variant Annotation Tool , 2015, Human mutation.

[26]  U. Weidle,et al.  L1-CAM as a target for treatment of cancer with monoclonal antibodies. , 2009, Anticancer research.

[27]  P. Altevogt,et al.  L1CAM , 2012, Cell adhesion & migration.

[28]  V. Golubovskaya.  Targeting FAK in human cancer: from finding to first clinical trials. , 2014, Frontiers in bioscience.

[29]  W. Dalton,et al.  Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR. , 2001, Molecular cancer therapeutics.

[30]  Steven A. Roberts,et al.  An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers , 2013, Nature Genetics.

[31]  M. Goodman,et al.  Stochastic properties of processive cytidine DNA deaminases AID and APOBEC3G , 2009, Philosophical Transactions of the Royal Society B: Biological Sciences.

[32]  Gad Getz,et al.  Somatic ERCC2 Mutations Are Associated with a Distinct Genomic Signature in Urothelial Tumors , 2016, Nature Genetics.

[33]  R. Durbin,et al.  The Sequence Ontology: a tool for the unification of genome annotations , 2005, Genome Biology.

[34]  M. Gregory,et al.  Human Pol ζ purified with accessory subunits is active in translesion DNA synthesis and complements Pol η in cisplatin bypass , 2014, Proceedings of the National Academy of Sciences.

[35]  M. Knowles,et al.  Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity , 2014, Nature Reviews Cancer.

[36]  Sergio Ricci,et al.  Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  P. Altevogt,et al.  Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma. , 2012, Cancer letters.

[38]  Hao Zhang,et al.  Beta 1-integrin protects hepatoma cells from chemotherapy induced apoptosis via a mitogen-activated protein kinase dependent pathway. , 2002, Cancer.

[39]  D. Hunting,et al.  Cisplatin Enhances the Formation of DNA Single- and Double-Strand Breaks by Hydrated Electrons and Hydroxyl Radicals , 2013, Radiation research.

[40]  J. Bellmunt,et al.  New therapeutic challenges in advanced bladder cancer. , 2012, Seminars in oncology.

[41]  Dmitry A. Gordenin,et al.  Hypermutation in human cancer genomes: footprints and mechanisms , 2014, Nature Reviews Cancer.

[42]  Levi Garraway,et al.  SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines , 2008, Nucleic acids research.

[43]  Nils Cordes,et al.  Signalling via integrins: implications for cell survival and anticancer strategies. , 2007, Biochimica et biophysica acta.

[44]  A. Montgomery,et al.  Involvement of integrin alpha(v)beta(3) and cell adhesion molecule L1 in transendothelial migration of melanoma cells. , 2001, Molecular biology of the cell.

[45]  J. Damiano,et al.  Integrins as novel drug targets for overcoming innate drug resistance. , 2002, Current cancer drug targets.

[46]  L. Collette,et al.  Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  L. Garraway,et al.  Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. , 2016, JAMA oncology.

[48]  Alessandro Romanel,et al.  ASEQ: fast allele-specific studies from next-generation sequencing data , 2015, BMC Medical Genomics.

[49]  J. Rosenberg,et al.  Novel molecular targets for urothelial carcinoma , 2015, Expert opinion on therapeutic targets.

[50]  E. Lam,et al.  FOXP1 acts through a negative feedback loop to suppress FOXO-induced apoptosis , 2013, Cell Death and Differentiation.

[51]  D. Cheresh,et al.  Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. , 2015, Trends in cell biology.

[52]  Su In Lee,et al.  FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells , 2015, Oncotarget.

[53]  R. Rintoul,et al.  ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through β1 integrin-dependent activation of PI3-kinase , 2006, Cell Death and Differentiation.

[54]  Syed Haider,et al.  Ensembl BioMarts: a hub for data retrieval across taxonomic space , 2011, Database J. Biol. Databases Curation.

[55]  C. Ryu,et al.  L1 Cell Adhesion Molecule Is a Novel Therapeutic Target in Intrahepatic Cholangiocarcinoma , 2010, Clinical Cancer Research.

[56]  Ludmil B. Alexandrov,et al.  Abstract IA11: Signatures of mutational processes in human cancer , 2017 .

[57]  P. Altevogt,et al.  The RGD integrin binding site in human L1-CAM is important for nuclear signaling. , 2008, Experimental cell research.

[58]  Michael P. Schroeder,et al.  In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities. , 2015, Cancer cell.

[59]  Lela Lackey,et al.  APOBEC3B and AID have similar nuclear import mechanisms. , 2012, Journal of molecular biology.

[60]  O. Elemento,et al.  Genome-Wide Detection of Genes Targeted by Non-Ig Somatic Hypermutation in Lymphoma , 2012, PloS one.

[61]  S. Culine,et al.  Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[63]  W. Dalton,et al.  Mechanisms Associated with cell Adhesion Mediated Drug Resistance (CAM-DR) in Hematopoietic Malignancies , 2004, Cancer and Metastasis Reviews.

[64]  V. Preedy,et al.  European Organization for Research and Treatment of Cancer , 2010 .

[65]  Hao Zhang,et al.  β1‐integrin protects hepatoma cells from chemotherapy induced apoptosis via a mitogen‐activated protein kinase dependent pathway , 2002 .

[66]  Jialing Huang,et al.  The interferon-induced expression of APOBEC3G in human blood-brain barrier exerts a potent intrinsic immunity to block HIV-1 entry to central nervous system. , 2007, Virology.

[67]  P. Altevogt,et al.  alpha5-integrin is crucial for L1CAM-mediated chemoresistance in pancreatic adenocarcinoma. , 2009, International journal of oncology.

[68]  P. Altevogt,et al.  Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells , 2007, Oncogene.

[69]  L. Collette,et al.  Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. , 2006, European journal of cancer.

[70]  Raquel Herrador,et al.  Rad51-mediated replication fork reversal is a global response to genotoxic treatments in human cells , 2015, The Journal of cell biology.

[71]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[72]  Z. Suo,et al.  TSPAN8 promotes gastric cancer growth and metastasis via ERK MAPK pathway. , 2015, International journal of clinical and experimental medicine.

[73]  C. Boucheix,et al.  E-cadherin/p120-catenin and tetraspanin Co-029 cooperate for cell motility control in human colon carcinoma. , 2010, Cancer research.

[74]  P. Mieczkowski,et al.  APOBEC3A and APOBEC3B Preferentially Deaminate the Lagging Strand Template during DNA Replication. , 2016, Cell reports.

[75]  N. Cordes,et al.  Focal adhesion signaling and therapy resistance in cancer. , 2015, Seminars in cancer biology.

[76]  Alessandro Romanel,et al.  Unraveling the clonal hierarchy of somatic genomic aberrations , 2014, Genome Biology.

[77]  J. Richie,et al.  Bladder cancer. Clinical practice guidelines in oncology. , 2005, Journal of the National Comprehensive Cancer Network : JNCCN.